Tessa K. Novick

Tessa K. Novick

Auto-generated profile, based on publicly available information

Tessa K. Novick

University of Texas at Austin Dell Medical School, Austin, Texas

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
ABAllison M. Bonds
Allison M. Bonds
TNTessa K. Novick
Tessa K. Novick
JDJessica B. Dietert
Jessica B. Dietert
FAFarshid Y. Araghizadeh
Farshid Y. Araghizadeh
COCraig H. Olson
Craig H. Olson
Surgical site infections in colorectal surgery remain a common problem, and are associated with an increase in cost of care and length of stay. This study aims to evaluate the effect of known risk factors and the use of incisional negative pressure wound therapy on surgical site infection rates. This is a single-center retrospective study with the use of chart review. The study took place at a tertiary academic medical center. All patients undergoing open colectomy at a single institution from 2009 through 2011 were studied. The primary outcome measured was the presence or absence of surgical site infection. Overall, 69 of the 254 patients (27.2%) experienced surgical site infection; 4 (12.5%) surgical site infections were seen in patients undergoing incisional negative pressure wound therapy and 65 (29.3%) were seen in patients undergoing standard closure. Multiple logistic regression revealed 2 significant factors: diabetes mellitus increased the chance of surgical site infection (OR, 1.98; p < 0.05), and the use of incisional negative pressure wound therapy decreased the chance of surgical site infection (OR, 0.32; p < 0.05). Obesity was associated with a trend toward increasing surgical site infection (OR, 1.64; p = 0.10). This study is limited by its retrospective nature and the high baseline prevalence of surgical site infection. Incisional negative pressure wound therapy appears to reduce surgical site infection in open colorectal surgery. Further study may be helpful to identify patient populations who would have the greatest benefit from this technique(see Video, Supplemental Digital Content 1, http://links.lww.com/DCR/A115).

1 May 2019 in Seminars in Nephrology
Verified
Journal Article
Closed access
DCDeidra C. Crews
Deidra C. Crews
TNTessa K. Novick
Tessa K. Novick

1 September 2017 in Medicine
Verified
Journal Article
Open access
TNTessa K. Novick
Tessa K. Novick
MCMichael J. Choi
Michael J. Choi
ARAvi Z. Rosenberg
Avi Z. Rosenberg
BMBlaithin A. McMahon
Blaithin A. McMahon
DFDerek Fine
Derek Fine
MAMohamed G. Atta
Mohamed G. Atta
Tenofovir alafenamide (TAF) is novel prodrug of Tenofovir, a nucleotide reverse transcriptase inhibitor. TAF is less nephrotoxic than its predecessor prodrug, tenofovir disoproxil fumarate (TDF). Tenofovir causes mitochondrial dysfunction and tubular injury when there is elevated accumulation in proximal tubule cells. TAF's unique pharmacokinetic profile enables provision of lower required doses for antiviral efficacy. Lower concentrations reach renal tubules minimizing intracellular accumulation and mitochondrial damage. TAF has not been associated with the histologic markers of tenofovir-associated nephrotoxicity that are seen with TDF, such as dysmorphic mitochondria in proximal tubule cells. Here, we report a patient with dysmorphic mitochondria on kidney biopsy after initiating therapy with TAF. This case suggests that at risk individuals may experience tubular mitochondrial injury from lower concentrations of tenofovir with TAF.

3 October 2019 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
TNTessa K. Novick
Tessa K. Novick
ASAditya Surapaneni
Aditya Surapaneni
JSJung-Im Shin
Jung-Im Shin
GAG. Caleb Alexander
G. Caleb Alexander
LILesley A. Inker
Lesley A. Inker
MGMorgan E. Grams
Morgan E. Grams
Background and objectives: Most opioids undergo kidney excretion. The goal of this study was to evaluate opioid-associated risks of death and hospitalization across the range of eGFR.Design, setting, participants, & measurements: The study population included adult primary care patients in Geisinger Health (Danville, PA) between 2008 and 2017. People receiving their first opioid prescription were propensity matched to people receiving NSAIDS (and, in sensitivity analysis, gabapentinoids) and the risk of death and hospitalization were compared, classifying opioid medication exposure as time-varying daily oral morphine milligram equivalents (MMEs) across time-varying eGFR.Results: The propensity-matched cohort included 46,246 patients prescribed either opioids or NSAIDs between 2008 and 2017 (mean [SD] age, 54 [16] years; 56% female; 3% of black race). Prescriptions for 1–59 and ≥60 MMEs were associated with higher risk of death (HR, 1.70; 95% CI, 1.41 to 2.05 for 1–59 MMEs; HR, 2.25; 95% CI, 1.82 to 2.79 for ≥60 MMEs) and hospitalization (HR, 1.38; 95% CI, 1.30 to 1.46 for 1–59 MMEs; HR, 1.68; 95% CI, 1.56 to 1.81 for ≥60 MMEs) compared with NSAID prescriptions, when evaluated at eGFR 80 ml/min per 1.73 m2. The relative risk of death associated with ≥60 MMEs was higher at lower GFR (e.g., eGFR, 40 ml/min per 1.73 m2; HR, 3.94; 95% CI, 2.70 to 5.75;Pfor interaction, 0.01). When gabapentinoids were used as the comparison medication, only ≥60 MMEs were significantly associated with higher risk of death (HR, 2.72; 95% CI, 1.71 to 4.34), although both 1–59 and ≥60 MMEs were associated with risk of hospitalization (HR, 1.22; 95% CI, 1.04 to 1.43 for 1–59 MMEs; HR, 1.54; 95% CI, 1.28 to 1.86 for ≥60 MMEs).Conclusions: The receipt of prescription opioids was associated with a higher risk of death and hospitalization compared with other pain medications, particularly with higher doses and at lower eGFR.

1 May 2018 in HIV/AIDS - Research and Palliative Care
Verified
Journal Article
Open access
PDF file
LPLaura Palau
Laura Palau
SMSteven Menez
Steven Menez
JRJavier Rodriguez-Sanchez
Javier Rodriguez-Sanchez
TNTessa Novick
Tessa Novick
MDMarco Delsante
Marco Delsante
MAMohamed G Atta
Mohamed G Atta
Despite the decreased incidence of human immunodeficiency virus (HIV)-associated nephropathy due to the widespread use of combined active antiretroviral therapy, it remains one of the leading causes of end-stage renal disease (ESRD) in HIV-1 seropositive patients. Patients usually present with low CD4 count, high viral load and heavy proteinuria, with the pathologic findings of collapsing focal segmental glomerulosclerosis. Increased susceptibility exists in individuals with African descent, largely due to polymorphism in APOL1 gene. Other clinical risk factors include high viral load and low CD4 count. Advanced kidney disease and nephrotic range proteinuria have been associated with progression to ESRD. Improvement in kidney function has been observed after initiation of combined active antiretroviral therapy. Other treatment options, when clinically indicated, are inhibition of the renin–angiotensin system and corticosteroids. Further routine management approaches for patients with chronic kidney disease should be implemented. In patients with progression to ESRD, kidney transplant should be pursued, provided that viral load control is adequate. Screening for the presence of kidney disease upon detection of HIV-1 seropositivity in high-risk populations is recommended.

3 January 2020 in Seminars in Dialysis
Verified
Journal Article
Closed access
PDF file
DCDeidra C. Crews
Deidra C. Crews
TNTessa K. Novick
Tessa K. Novick